Johnsen Steven A, Güngör Cenap, Prenzel Tanja, Riethdorf Sabine, Riethdorf Lutz, Taniguchi-Ishigaki Naoko, Rau Thomas, Tursun Baris, Furlow J David, Sauter Guido, Scheffner Martin, Pantel Klaus, Gannon Frank, Bach Ingolf
Department of Molecular Oncology, Göttingen Center for Molecular Biosciences, University of Göttingen, Justus-von-Liebig-Weg 11, 37077 Göttingen, Germany.
Cancer Res. 2009 Jan 1;69(1):128-36. doi: 10.1158/0008-5472.CAN-08-1630.
Mammary oncogenesis is profoundly influenced by signaling pathways controlled by estrogen receptor alpha (ERalpha). Although it is known that ERalpha exerts its oncogenic effect by stimulating the proliferation of many human breast cancers through the activation of target genes, our knowledge of the underlying transcriptional mechanisms remains limited. Our published work has shown that the in vivo activity of LIM homeodomain transcription factors (LIM-HD) is critically regulated by cofactors of LIM-HD proteins (CLIM) and the ubiquitin ligase RING finger LIM domain-interacting protein (RLIM). Here, we identify CLIM and RLIM as novel ERalpha cofactors that colocalize and interact with ERalpha in primary human breast tumors. We show that both cofactors associate with estrogen-responsive promoters and regulate the expression of endogenous ERalpha target genes in breast cancer cells. Surprisingly, our results indicate opposing functions of LIM cofactors for ERalpha and LIM-HDs: whereas CLIM enhances transcriptional activity of LIM-HDs, it inhibits transcriptional activation mediated by ERalpha on most target genes in vivo. In turn, the ubiquitin ligase RLIM inhibits transcriptional activity of LIM-HDs but enhances transcriptional activation of endogenous ERalpha target genes. Results from a human breast cancer tissue microarray of 1,335 patients revealed a highly significant correlation of elevated CLIM levels to ER/progesterone receptor positivity and poor differentiation of tumors. Combined, these results indicate that LIM cofactors CLIM and RLIM regulate the biological activity of ERalpha during the development of human breast cancer.
乳腺肿瘤发生受到雌激素受体α(ERα)所控制的信号通路的深刻影响。尽管已知ERα通过激活靶基因刺激许多人类乳腺癌的增殖来发挥其致癌作用,但我们对其潜在转录机制的了解仍然有限。我们已发表的研究表明,LIM同源结构域转录因子(LIM-HD)的体内活性受到LIM-HD蛋白的辅助因子(CLIM)和泛素连接酶RING指LIM结构域相互作用蛋白(RLIM)的严格调控。在此,我们鉴定出CLIM和RLIM是新型的ERα辅助因子,它们在原发性人类乳腺肿瘤中与ERα共定位并相互作用。我们表明这两种辅助因子均与雌激素反应性启动子相关联,并调节乳腺癌细胞中内源性ERα靶基因的表达。令人惊讶的是,我们的结果表明LIM辅助因子对ERα和LIM-HDs具有相反的功能:虽然CLIM增强LIM-HDs的转录活性,但在体内它抑制ERα介导的大多数靶基因的转录激活。反过来,泛素连接酶RLIM抑制LIM-HDs的转录活性,但增强内源性ERα靶基因的转录激活。对1335例患者的人类乳腺癌组织微阵列分析结果显示,CLIM水平升高与ER/孕激素受体阳性以及肿瘤低分化高度相关。综合来看,这些结果表明LIM辅助因子CLIM和RLIM在人类乳腺癌发生过程中调节ERα的生物学活性。